General Nuclear Medicine Track

The general nuclear medicine track features a wide-ranging scope of sessions developed and led by experts from SNMMI's specialty councils and centers of excellence. These sessions are designed to expand your knowledge on the latest clinical applications and best practices in the field advancing precision medicine.

Friday, February 25

2:00–3:30 pm ET

Filling the Gaps in Nuclear Medicine Resident Training: Simulation, Presentation, and Question-Writing Skills 
Sponsored by the SNMMI Academic Council, General Clinical Nuclear Medicine Council, Early Career Professionals Committee
Organizers: Twyla Bartel, DO, MBA, FACNM, FSNNMI; Darlene Metter, MD, FACNM, FSNMMI; Erica Cohen Major, DO, MPH, FACNM; Justin Peacock, MD, PhD
Moderators: Erica Cohen Major, DO, MPH, FACNM; Justin Peacock, MD, PhD


Session Objectives

  • Examine the potential new tool of software simulation for enhancement of a nuclear medicine resident program.
  • Discuss the principles of and be able to create an effective power point presentation.
  • Recognize the concept of and be able to write a focused item.


Presentations include:

  • Software Simulation for Enhancement of Nuclear Medicine Resident Education
    Frederick D. Grant, MD
  • How to Create an Effective PowerPoint Presentation
    Darlene Metter, MD, FACNM, FSNMMI
  • How to Write a Focused Question/Item
    Darlene Metter, MD, FACNM, FSNMMI
  • Q&A


3:45–5:15 pm ET

[18F]FDOPA: Applications, Implementation, and the Journey to FDA Approval
Sponsored by the SNMMI Radiopharmaceutical Sciences Council
Organizers: Amy Vavere, PhD; Michael Nickels, PhD
Moderator: Amy Vavere, PhD

Session Objectives

  • Describe clinical applications for diagnosis and prognosis in oncologic and non-oncologic conditions.
  • List synthetic approaches to the preparation of FDOPA for use in patients.
  • Discuss background and details on the submission and approval process from research tracer to FDA-approved PET drug.

Presentations include:

  • Applications of FDOPA in Clinical Practice and Research
    Abhishek Jha, MD
  • Review of the Synthesis and Production of [18F]FDOPA
    Michael Nickels, PhD
  • The Journey to FDA Approval of [18F]FDOPA
    Thomas C. Chaly, PhD
  • Q&A


5:30–7:00 pm ET

Updates in Theranostics in Prostate Cancer 
Sponsored by the  SNMMI Therapy Center of Excellence
Organizers: Neeta Pandit-Taskar, MD; Ephraim E.  Parent, MD, PhD
Moderators: Ephraim E.  Parent, MD, PhD; Daniel Lee, MD

Session Objectives

  • Discuss the use of various imaging agents in prostate cancer
  • Describe the indications and use of the RPT in prostate cancer
  • Examine new developments in prostate cancer evaluation and management


Presentations include:

  • Development is Imaging Prostate Cancer
    Steven P. Rowe, MD, PhD
  • Lu-177 PSMA:  Clinical Stats
    Robert Flavell, MD, PhD
  • Prostate Theranostics:  Vision Trial and Clinical Management Perspective
    Jingsong Zhang, MD, PhD
  • Lu-177 PSMA Therapy:  Practical Aspects for Clinical Application
    Ayse Tuba-Kendi, MD
  • Panel Discussion/Q&A


Saturday, February 26

10:00–11:30 am ET

Not So Common NM Studies and Their Anatomic Correlates
Sponsored by the SNMMI Correlative Imaging Council and Advanced Associate Council 
Organizer: Twyla Bartel, DO, MBA, FACNM, FSNMMI

Session Objectives

  • Review the preparation and imaging protocols of less common nuclear medicine studies from the technologist viewpoint
  • Confirm your understanding of how to correctly interpret these less-common studies
  • Educate on how to correlate these specific nuclear medicine cases with anatomic imaging


Presentations include:

  • Not So Common NM Studies and Their Anatomic Correlates
    Norman Bolus, MSPH, CNMT, FSNMMI-TS

    Twyla Bartel, DO, MBA, FACNM, FSNMMI
  • Q&A


11:45 am–1:15 pm ET

The Many Potential Roles of Fibroblast Activation Protein PET
Sponsored by the SNMMI Correlative Imaging Council
Organizer: Thomas A. Hope, MD
Moderators: Jeremie Calais, MD; Thomas A. Hope, MD

Session Objectives

  • Review the role of imaging fibroblast activation protein in cancer imaging
  • Evaluate the potential benefit of FAP-targeted radioligand therapy for treatment of metastatic cancer
  • Compare the potential benefit of FAP-targeted PET in benign fibrosis.

Presentations include:

  • 68Ga-FAPI-46 PET/CT in Cancer Patients: The UCLA Experience
    Jeremie Calais, MD
  • FAPI Targeted Radioligand Therapy of Sarcoma and Beyond
    Wolfgang P. Fendler, MD
  • FAP in the Non-Oncologic Setting
    Susan Notohamiprodjo, MD
  • Initial Experience with FAP-2286 Imaging
    Thomas A. Hope, MD
  • Q&A


2:30–4:00 pm ET

Infection/Inflammation Imaging: Where We Have Come from and the Expanding Role of FDG PET
Sponsored by the SNMMI PET Center of Excellence
Organizers: Twyla Bartel, DO, MBA, FACNM, FSNMMI; Darlene Metter, MD, FACNM, FSNMMI
Moderators: Esther Choi, MD, MS, CCD; Maria Liza Lindenberg, MD

Session Objectives

  • Review the basics of general nuclear medicine indications and techniques for infection/inflammation imaging
  • Discuss how FDG PET/CT has been utilized for infection/inflammation imaging and its expanding role
  • List the new and emerging developments in infection/inflammatory imaging


Presentations include:

  • Review of General Nuclear Medicine Infection/Inflammation Imaging
    Christopher Palestro, MD, FACNM, FSNMMI
  • FDG-PET/CT for Infection/Inflammation – “Tried & True” and Expanding Role
    Christopher Palestro, MD, FACNM, FSNMMI
  • New Developments in Infection and Inflammation
    Sanjay Jain, MD
  • Q&A


4:15–5:15 pm ET

Diversity Initiative at Stanford Radiology: How to be an Ally
Sponsored by the SNMMI Women in Nuclear Medicine and DE&I Committee
Organizers/Moderators: Hyewon Hyun, MD; Joanna R. Fair, MD, PhD

Session Objectives

  • Discuss career issues that affect all faculty and career issues that are female specific.
  • Increase awareness of implicit bias and systemic racism in radiology and nuclear medicine
  • Provide examples for diversity related education, pipeline programs and effective allyship


Presentations include:

  • Diversity Initiative at Stanford Radiology: How to be an Ally
    Heike E. Daldrup-Link, MD, PhD
  • Q&A


Sunday, February 27

10:00–11:30 am ET

Nuts and Bolts of Image Quantification and Associated AI Applications
Sponsored by the SNMMI Physics, Instrumentation and Data Sciences Council
Organizers/Moderators: R. Glenn Wells, PhD; Chi Liu, PhD

Session Objectives

  • Review the steps and corrections needed to quantify SPECT and PET images
  • Recognize potential sources of error and the levels of quantitation achievable for PET and SPECT
  • Describe how state-of-the-art artificial intelligence methods are being applied to image quantification


Presentations include:

  • Quantification of SPECT and PET
    R. Glenn Wells, PhD
  • Applying Artificial Intelligence to Image Quantification
    Chi Liu, PhD
  • Q&A

11:45 am–1:15 pm ET

GU Made Simple/Nucs After Dark
Sponsored by the SNMMI Pediatric Council/General Clinical Nuclear Medicine Council
Organizers/Moderators: Darlene Metter, MD, FACR, FACNM, FSNMMI; Lisa J. States, MD

Session Objectives

  • Describe basic renal imaging in assessing obstruction.
  • Interpret imaging in renal transplant, GU infection and GI bleeds.
  • Provide a concise VQ report in pulmonary embolism. 


Presentations include:

  • GU Made Simple – UTI; Diuresis Renography
    Eglal Shalaby-Rana, MD
  • Nucs After Dark– GI Bleed
    Lisa J. States, MD
  • GU Made Simple – Renal Transplant
    Reza Vali
  • GU Basics to Include Obstruction
    Nucs after Dark – VQ
    Darlene Metter, MD, FACR, FACNM, FSNMMI
  • Q&A


2:30–4:00 pm ET


Amyloid Imaging: Advantages and Pitfalls to Aid Treatment of Alzheimer’s Disease
Sponsored by the SNMMI Brain Imaging Council
Organizer/Moderators: Tanyaluck Thientunyakit, MD; Igor Yakushev, MD

Session Objectives

  • Examine the role of amyloid imaging in the management of dementia disorders
  • Discuss the principles of reading of amyloid PET images
  • Describe the role of amyloid imaging in the targeted therapy of Alzheimer’s disease


Presentations include:

  • Amyloid Imaging in the Management of Patients with Suspected Dementia Disorder
    Igor Yakushev, MD
  • Nuts and Bolts: How to Read Amyloid PET Images
    Tanyaluck Thientunyakit, MD, FANMB
  • Brain Molecular Imaging in the Context of Anti-Amyloid Therapies
    Satoshi Minoshima, MD, PhD,  FSNMMI
  • Q&A

 

4:15–5:45 pm ET

Implementing Newly FDA-Approved PET/CT Imaging Agents
Sponsored by the SNMMI Clinical Trials Network and PET Center of Excellence
Organizers: Regan Butterfield, BS, CNMT ARRT(CT); Gary Ulaner, MD, PhD, FACNM
Moderators: Gary Ulaner, MD, PhD, FACNM; Steven Rowe, MD, PhD


Session Objectives

  • Review the indications and mechanisms of action of 18F-FES, 64Cu-DOTATATE, and 18F-DCFPyL.
  • Examine normal biodistribution of 18F-FES, 64Cu-DOTATATE, and 18F-DCFPyL.
  • Discuss PET/CT imaging interpretation for 18F-FES, 64Cu-DOTATATE, and 18F-DCFPyL


Presentations include:

  • 18F-Fluoroestradiol
    Gary Ulaner, MD, PhD, FACNM
  • 64Cu-DOTATATE
    Erik Mittra, MD, PhD
  • 18F-DCFPyl
    Steve Rowe, MD, PhD
  • Q&A